Table 5

Time to progression and survival

Initial stagePeak IgM titerTTP (mo.)Site of progressionSurvival (mo.)
Polysialic acid
 Patient 1ExtensiveNE1Leptomeninges1
 Patient 2Extensive (pleural effusion)1037+
 Patient 3Limited035+
 Patient 4Limited16036+
 Patient 5Extensive402Brain10
 Patient 6Extensive034+
 Patient 7LimitedNE5Chest34+
NP-polysialic acida
 Patient 1Limited12805Brain11
 Patient 2Extensive1602Chest26
 Patient 3Extensive12803Chest24
 Patient 4Extensive402Lung, liver, bone marrow3
 Patient 5Extensive6403Brain8
 Patient 6Limited128029 +
  • a NP, N-propionylated.